Herzuma® 

 

Herzuma, biosimilar trastuzumab, that is delivered intravenously, is licensed for the treatment of patients with early breast cancer, metastatic breast cancer or metastatic gastric cancer whose tumours have either HER2 overexpression or HER2 gene amplification.1

Trastuzumab is a monoclonal antibody designed to target the HER2 receptor. When it binds to the receptor, trastuzumab reduces HER2 signalling that otherwise increases tumour stimulation, and also enables the immune system to target the cancerous tumour. 2

Herzuma is administered on its own as monotherapy as well as in combination with, or following, standard chemotherapy. Trastuzumab has changed the prognosis of patients with HER2 positive breast cancer, both in advanced and early stage disease. 3

 

References

  1. Herzuma® (i.v. trastuzumab) Summary of Product Characteristics. Available at: www.medicines.ie
  2. Gajria D, et al. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer ther. 2011 Fe: 11 (2): 263-275
  3. Bartsch, R et al. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 2007; 1(1): 19–31